Sunesis Pharmaceuticals (SNSS) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-20.53M
Stock-based compensation expense	2.66M
Depreciation and amortization	6K
Change in fair value of warrant liability
Foreign exchange gain on marketable securities
Gain on sale of property and equipment
Prepaids and other assets	-273K
Accounts payable	306K
Accrued clinical expense	52K
Accrued compensation	-493K
Other accrued liabilities	-876K
Net cash used in operating activities
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of marketable securities	-57.42M
Proceeds from maturities of marketable securities	53.3M
Net cash (used in) provided by investing activities
Proceeds from issuance of common stock through controlled equity offering facilities, net
Proceeds from issuance of common stock in third closing of private placement
Proceeds from exercise of stock options and from employee stock purchase plan
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents	-17.44M
Cash and cash equivalents at beginning of period	26.89M
Cash and cash equivalents at end of period	9.45M

Entities mentioned with SNSS

View All Entities